62 results
8-K
EX-99.1
FGEN
FibroGen Inc
29 Aug 23
FibroGen Announces Topline Results from LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Ambulatory Duchenne Muscular Dystrophy
5:14pm
of patients, their caregivers, the advocacy community, and the trial investigators who have contributed to this important clinical study. We … are committed to sharing all learnings from this trial with the Duchenne community and hope that there are insights that may help future efforts to develop
8-K
EX-99.2
FGEN
FibroGen Inc
12 Nov 19
FibroGen Reports Third Quarter 2019 Financial Results
8:16am
as an important endpoint in the nephrology community.
In non-dialysis where roxadustat was compared to placebo, which is the gold standard in safety … , which was celebrated in China with much enthusiasm. The Chinese nephrology community envisions itself as leading the way internationally in the adoption
8-K
EX-99.1
FGEN
FibroGen Inc
20 Sep 19
Roxadustat Approved in Japan for the Treatment of Anemia Associated with Chronic Kidney Disease in Dialysis Patients
9:00am
of people worldwide and expanding treatment options, especially within the dialysis community where there is high-unmet need. We are delighted to bring
S-1
EX-10.1
FGEN
FibroGen Inc
1 Oct 14
IPO registration
12:00am
as community property or otherwise, if any, in the option granted hereunder, and in any ISO Shares purchased pursuant to this Agreement.
(Optionee’s Spouse … indicates by the execution of this Notice of Exercise his or her consent to be bound by the terms herein as to his or her interests, whether as community
S-1
EX-10.2
FGEN
FibroGen Inc
1 Oct 14
IPO registration
12:00am
by the terms thereof as to his or her interests, whether as community property or otherwise, if any, in the option granted hereunder, and in any ISO Shares
S-1/A
EX-10.18
c91qr
20 Oct 14
IPO registration (amended)
12:00am
10-Q
jae58py2hggv0aq0h6c
12 May 15
Quarterly report
12:00am